Q3332925 (Q3332925): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): Development of a new pharmaceutical formulation for medical use in serious diseases., translated_summary) |
||||||||||||||
| Property / summary | |||||||||||||||
Development of a new pharmaceutical formulation for medical use in serious diseases. (English) | |||||||||||||||
| Property / summary: Development of a new pharmaceutical formulation for medical use in serious diseases. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Development of a new pharmaceutical formulation for medical use in serious diseases. (English) / qualifier | |||||||||||||||
point in time: 25 October 2021
| |||||||||||||||
Revision as of 07:55, 25 October 2021
Project Q3332925 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3332925 in Germany |
Statements
876,460.35 Euro
0 references
1,864,809.26 Euro
0 references
47.0 percent
0 references
1 December 2015
0 references
31 October 2020
0 references
PROTEO Biotech AG
0 references
24106 Kiel
0 references
Entwicklung einer neuen pharmazeutischen Formulierung für die medizinische Anwendung bei schwerwiegenden Erkrankungen. (German)
0 references
Development of a new pharmaceutical formulation for medical use in serious diseases. (English)
25 October 2021
0 references
Identifiers
DE_TEMPORARY_35570
0 references